Catalyst Pharmaceuticals (CPRX) FCF Margin (2018 - 2026)

Catalyst Pharmaceuticals' FCF Margin history runs 9 years deep, the most recent figure standing at 39.87% for Q1 2026.

• Quarterly FCF Margin fell 259.0% year-over-year to 39.87% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34.86% (down 1518.0% YoY) and the FY2025 annual result came in at 35.42%, down 1324.0% from the prior year.
• FCF Margin was 39.87% for Q1 2026 at Catalyst Pharmaceuticals, up from 29.39% in the prior quarter.
• Across five years, FCF Margin topped out at 72.15% in Q3 2022 and bottomed at 14.05% in Q1 2023.
• A 5-year average of 42.3% and a median of 43.88% in 2023 frame the typical range for FCF Margin.
• Annual changes were most pronounced in 2024 — FCF Margin soared 2137 bps — and 2025, when it sank 3456 bps.
• Catalyst Pharmaceuticals' FCF Margin stood at 65.96% in 2022, then decreased by 24 bps to 50.25% in 2023, then dropped by 1 bps to 49.91% in 2024, then tumbled by 41 bps to 29.39% in 2025, then surged by 36 bps to 39.87% in 2026.
• Business Quant data shows CPRX's FCF Margin at 39.87% in Q1 2026, 29.39% in Q4 2025, and 21.86% in Q3 2025.